BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21036213)

  • 1. Photodynamic therapy for polypoidal choroidal vasculopathy.
    Chhablani JK
    Am J Ophthalmol; 2010 Nov; 150(5):754-5; author reply 755. PubMed ID: 21036213
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy.
    Sato T; Kishi S; Matsumoto H; Mukai R
    Am J Ophthalmol; 2010 Jun; 149(6):947-954.e1. PubMed ID: 20346441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of combined photodynamic therapy and intravitreal bevacizumab injection versus photodynamic therapy alone in polypoidal choroidal vasculopathy.
    Kim SJ; Yu HG
    Retina; 2011 Oct; 31(9):1827-34. PubMed ID: 21734621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.
    Gomi F; Sawa M; Wakabayashi T; Sasamoto Y; Suzuki M; Tsujikawa M
    Am J Ophthalmol; 2010 Jul; 150(1):48-54.e1. PubMed ID: 20609707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy.
    Rouvas AA; Papakostas TD; Ntouraki A; Douvali M; Vergados I; Ladas ID
    Retina; 2011 Mar; 31(3):464-74. PubMed ID: 20948458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
    Maruko I; Iida T; Sugano Y; Saito M; Sekiryu T
    Am J Ophthalmol; 2011 Apr; 151(4):594-603.e1. PubMed ID: 21295766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
    Chhablani J
    Am J Ophthalmol; 2010 Sep; 150(3):443-4; author reply 444. PubMed ID: 20728684
    [No Abstract]   [Full Text] [Related]  

  • 8. Sequential therapy with intravitreal bevacizumab and photodynamic therapy for idiopathic polypoidal choroidal vasculopathy.
    Pai SA; Shetty R
    Acta Ophthalmol; 2009 Nov; 87(7):806-7. PubMed ID: 18721250
    [No Abstract]   [Full Text] [Related]  

  • 9. Intravitreal ranibizumab combined with verteporfin photodynamic therapy for treating polypoidal choroidal vasculopathy.
    Lee YH; Lee EK; Shin KS; Lee KM; Kim JY
    Retina; 2011; 31(7):1287-93. PubMed ID: 21386762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab.
    Tomita K; Tsujikawa A; Yamashiro K; Ooto S; Tamura H; Otani A; Nakayama Y; Yoshimura N
    Am J Ophthalmol; 2012 Jan; 153(1):68-80.e1. PubMed ID: 21907965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up.
    Lee YA; Yang CH; Yang CM; Ho TC; Lin CP; Huang JS; Chen MS
    Am J Ophthalmol; 2012 Nov; 154(5):872-880.e2. PubMed ID: 22831838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
    Saito M; Iida T; Kano M
    Retina; 2012 Jul; 32(7):1272-9. PubMed ID: 22547209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.
    Cheng CK; Peng CH; Chang CK; Hu CC; Chen LJ
    Retina; 2011 May; 31(5):846-56. PubMed ID: 21317837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3 years of follow-up.
    Leal S; Silva R; Figueira J; Cachulo ML; Pires I; de Abreu JR; Cunha-Vaz JG
    Retina; 2010 Sep; 30(8):1197-205. PubMed ID: 20827139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.
    Moon SW; Kim MS; Kim ES; Yu SY; Kwak HW
    Ophthalmologica; 2011; 225(3):169-75. PubMed ID: 21273795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
    Sato T; Kishi S; Matsumoto H; Mukai R
    Am J Ophthalmol; 2013 Jul; 156(1):95-105.e1. PubMed ID: 23628354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab.
    Tsujikawa A; Ooto S; Yamashiro K; Tamura H; Otani A; Yoshimura N
    Jpn J Ophthalmol; 2010 Jul; 54(4):310-9. PubMed ID: 20700799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Necessity of paracentesis before or after intravitreal injection of bevacizumab.
    Huang WC; Lin JM; Chiang CC; Tsai YY
    Arch Ophthalmol; 2008 Sep; 126(9):1314-5; author reply 1315. PubMed ID: 18779502
    [No Abstract]   [Full Text] [Related]  

  • 19. Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study.
    Lim JY; Lee SY; Kim JG; Lee JY; Chung H; Yoon YH
    Acta Ophthalmol; 2012 Feb; 90(1):61-7. PubMed ID: 20337606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
    Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
    Retina; 2006; 26(9):988-93. PubMed ID: 17151484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.